penfluridol
Enable an agent to identify penfluridol, assess the identity and condition of a material sample, and determine which handling or use decisions its evidence supports.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 17 findings · 27 questions
Penfluridol identity Resolve the registered name to the parent molecule and keep related chemical forms and products distinct.
Molecular recognition
Establish agreement between the proposed structure and penfluridol identifiers.
Parent structure match
Record structural evidence sufficient to distinguish penfluridol from similarly named or pharmacologically related compounds.
- Does the candidate structure match the penfluridol reference connectivity and InChIKey? definition
- Which inspected reference supports the mapping between that structure, CAS 26864-56-2, and CID 33630? provenance
Substance and product boundary
Separate the parent substance from alternate forms, mixtures, and finished medicines.
Represented material
Identify precisely what a label or record represents before inheriting penfluridol properties.
- Does this record represent parent penfluridol, an explicitly characterized alternative chemical form, or a mixture containing it? boundary
- Which product or formulation model owns any brand, tablet strength, excipients, and release behavior? boundary
Penfluridol material quality Determine what a particular batch contains and what its analytical evidence establishes.
Batch authentication
Connect a physical sample to provenance and identity testing.
Traceable identity evidence
Require sample-specific links between batch records, reference materials, and identity measurements.
- Which supplier, lot, certificate, and sampling record identify this penfluridol material? provenance
- Which orthogonal analytical results support identity rather than merely reproducing the supplier's label? measurement
Content and contaminants
Record penfluridol content and material components that affect interpretation or suitability.
Assay basis and impurities
Keep quantitative content, chromatographic purity, residual solvents, water, and degradation products distinguishable.
- Is the reported penfluridol assay mass-based, dry-basis, or chromatographic area percentage, and how was it calibrated? measurement
- Which identified and unidentified impurities were measured, with what detection limits and intended-use acceptance criteria? measurement
Penfluridol physical behavior Describe form-dependent behavior during storage, characterization, and solution preparation.
Solid state and stability
Connect solid-state observations and storage history to material condition.
Form and integrity
Record measured phase, thermal transitions, and evidence of change without assuming an established polymorph catalogue.
- What solid form and melting or decomposition behavior were measured for this penfluridol sample, using which methods? measurement
- Do storage history and repeat analysis support continued use, or require quarantine and reassessment? action
Solution preparation
Establish the conditions under which the intended penfluridol concentration is available in solution.
Dissolved concentration
Distinguish nominal loading from measured dissolved material and track changes after dilution.
- What solubility is measured in the proposed solvent or assay medium at the relevant pH and temperature? measurement
- Does dilution or storage cause precipitation, adsorption loss, or degradation that changes the available penfluridol concentration? measurement
Penfluridol biological evidence Organize evidence for target activity and prolonged action while preserving experimental context.
Target and effect evidence
Distinguish target binding, functional effects, and downstream observations.
Activity interpretation
Attach each proposed mechanism or effect to the assay and exposure that support it.
- Which direct assays establish penfluridol activity at dopamine D2 or other proposed targets, and what endpoints do they measure? provenance
- Are reported downstream effects distinguished from target engagement and nonspecific toxicity at the tested concentrations? boundary
Persistence and exposure
Capture the evidence underlying long duration of action.
Duration evidence
Separate measured elimination, tissue persistence, and pharmacodynamic duration rather than equating them.
- Which species, route, formulation, regimen, and sampling window support each reported penfluridol half-life? measurement
- What evidence separates effects of parent penfluridol, metabolites, tissue distribution, and formulation on observed duration? boundary
Penfluridol handling and use Connect material handling and intended use to applicable evidence and authority.
Laboratory exposure control
Establish applicable precautions for penfluridol powder, solutions, and waste.
Handling evidence
Use an applicable safety record and task-specific exposure assessment without inventing a universal hazard classification.
- Which dated SDS and jurisdiction support the hazard classification of this penfluridol material? provenance
- What containment, protective equipment, spill response, and waste route are supported for the quantity and physical form being handled? action
Permitted use context
Separate material grade and research use from medicinal product authorization.
Use eligibility
Record the evidence needed before a specific material is accepted for its proposed use.
- What specification and documentation qualify this penfluridol batch for the proposed research or pharmaceutical purpose? action
- Which current jurisdiction-specific product record governs any medicinal-use claim, and where is that product modeled? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of penfluridol this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of penfluridol this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of penfluridol this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of penfluridol this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of penfluridol this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of penfluridol this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of penfluridol this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Penfluridol is a synthetic, long-acting diphenylbutylpiperidine antipsychotic whose dopamine D2 receptor antagonism supports its use in treating schizophrenia.
In scope
- Molecular identity and cross-registry identifiers for penfluridol
- Chemical form, solid form, purity, impurities, and batch traceability
- Condition-dependent physical properties, solubility, and stability
- Evidence for pharmacological activity and persistence
- Substance hazards and jurisdiction-specific constraints on intended use
Out of scope
- Finished tablets, brands, packaging, and excipient formulations
- Patient diagnosis, prescribing, dose selection, and treatment monitoring
- Manufacturing routes and production equipment
- Separate molecular models for metabolites or related antipsychotics
- Clinical trials and disease models beyond their evidence links to penfluridol
Why it exists Filled
Enable an agent to identify penfluridol, assess the identity and condition of a material sample, and determine which handling or use decisions its evidence supports.
Distinguishing features Filled
- The neutral parent must match C28H27ClF5NO and InChIKey MDLAAYDRRZXJIF-UHFFFAOYSA-N; the formula alone does not establish connectivity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)
- Its structure combines a piperidin-4-ol bearing a chlorotrifluoromethylphenyl group with an N-linked bis(4-fluorophenyl)butyl group, distinguishing it from related antipsychotics such as pimozide and haloperidol. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)
- CAS 26864-56-2, PubChem CID 33630, and EC 248-074-5 should resolve consistently to the parent substance. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Penfluridol)
- A tablet or branded medicine containing penfluridol is a related product, not an interchangeable representation of the isolated substance.
- Long-acting antipsychotic activity is a supporting role description, not an identity test or evidence that a particular sample is fit for medicinal use. [NCBI MeSH](https://www.ncbi.nlm.nih.gov/mesh/68010395)
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust penfluridol for a specific person.
- Suggest giving antipsychotics to someone without their knowledge or consent.
- Advise stopping antipsychotic treatment without a clinician.
- Stigmatize people who take antipsychotics.
Only with a human decision
- Starting, stopping or changing antipsychotic treatment for a patient.
May
- Explain penfluridol as a long-acting oral antipsychotic and where it is authorized, from official sources.
- Report warnings and side effects from official labelling.
Moral aspects Filled
- Antipsychotic treatment touches autonomy, consent and the risk of coercion.
- People with schizophrenia face stigma that careless language worsens.
Who is affected
- Patients with psychotic disorders
- Families and carers
- Prescribers
Owners Filled
Steward
The prescriber and the pharmacist for each patient; medicines regulators authorize products.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.penfluridol
- Wikidata: Q2149707 (https://www.wikidata.org/wiki/Q2149707)
Direct properties required Filled
- Parent molecular identity: C28H27ClF5NO; InChIKey MDLAAYDRRZXJIF-UHFFFAOYSA-N
- Registry identifier concordance: vr.tr.penfluridol; CAS 26864-56-2; PubChem CID 33630; EC 248-074-5
- Chemical and solid form: Parent or explicitly identified alternative form; crystalline, amorphous, or unresolved; supporting analytical method
- Assay and impurity profile: % w/w assay with reporting basis; individual impurities in % w/w or ppm; chromatographic area % separately identified
- Solubility: mg/mL or mol/L with solvent, pH, temperature, chemical form, and equilibration method
- Thermal behavior: Melting range or decomposition onset in °C with method; boiling behavior only if experimentally established
- Stability and storage condition: Within specification, degraded, or unassessed; temperature, light, moisture, container, and elapsed time
- Target activity: Ki, Kd, IC50, or EC50 in nM or µM with target, species, assay, and endpoint
- Pharmacokinetic persistence: Half-life in hours or days with species, route, formulation, regimen, sampling window, and estimation method
- Hazard and use status: Dated SDS and classification source; jurisdiction; research or medicinal context; applicable restrictions
Recognition required Filled
- Identified by product label, active ingredient name and pack details rather than by appearance alone.
Capabilities and actions required Filled
- Match a candidate substance record to penfluridol using structure and concordant identifiers.
- Evaluate whether a batch's analytical evidence supports its claimed identity, content, and grade.
- Assess whether a proposed solvent and concentration are supported by measured solubility evidence.
- Flag storage excursions or degradation evidence that require sample reassessment.
- Compare penfluridol activity and persistence measurements within compatible experimental contexts.
- Route handling and use decisions to applicable safety evidence and jurisdiction-specific records.
Hazards and failure modes required Filled
- Movement disorders.
- Heart rhythm effects.
- Sedation and impaired driving.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns penfluridol code N05AG03 within diphenylbutylpiperidine antipsychotics.
Context of use required Filled
- Penfluridol is encountered in pharmaceutical research, chemical reference materials and medicinal products where it is authorized.
- Its long duration of action supports its use as an oral antipsychotic for schizophrenia under clinical supervision.
Sources Filled
- Wikidata item Q2149707: penfluridol - identity and sense of the item
- Wikipedia: Penfluridol - general description of the item
Open questions
- Which authoritative specifications establish penfluridol assay methods, impurity limits, and reference-standard requirements for each intended grade?
- Which experimentally established solid forms, melting ranges, and decomposition behaviors belong to the parent substance rather than an alternative form or supplier-specific sample?
- What validated pH-dependent solubility and stability data support aqueous assay preparation and stock-solution storage?
- Which primary studies establish target selectivity, human pharmacokinetic variability, and the contributions of metabolites or tissue distribution to prolonged action?
- Which current jurisdiction-specific records establish applicable GHS classifications, any substance-specific occupational exposure limit, and authorized medicinal products?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q2149707/spec.json